Oxeia Biopharmaceuticals develops novel therapeutics for patients with concussions.

Because rest is not enough

Join the mission to bring the first FDA-approved treatment for persistent concussion symptoms to market. Visit our campaign page on StartEngine.

This Reg CF offering is made available through StartEngine Primary LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

What’s New…

Oxeia Biopharma In the News
Crowdfunding for Biotechs

Oxeia CEO Michael Wyand writes in MedNous about how Regulation CF/A+ enables clinical-stage biotechs to fund drug development while keeping traditional financing options open.

Read More →
Oxeia Pioneering First Potential FDA-Approved Concussion Treatment, Launches Equity Crowdfunding Campaign to Fund Phase 2b Development

Biotech showed 85% patient improvement in Phase 2a trial—zero approved treatments exist for persistent concussion symptoms

Read More →
 

These stories and more…

Read more...

Oxeia Biopharmaceuticals is a team of passionate scientists, biotech leaders, and athletes dedicated to bringing a safe and effective concussion therapy to market.

REST IS NOT ENOUGH.

More About What We Do